(Q24642721)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Myocarditis and cardiomyopathy associated with clozapine

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Physician patterns of metabolic screening for patients taking atypical antipsychotics: a retrospective database study

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Differential metabolic effects of antipsychotic treatments

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

New-onset type-2 diabetes associated with atypical antipsychotic medications.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Sexuality and schizophrenia: a review

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Adverse cardiac effects associated with clozapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Twice-yearly exams unnecessary for patients taking quetiapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Physical health monitoring of patients with schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

The effects of antipsychotic therapy on serum lipids: a comprehensive review.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Consensus development conference on antipsychotic drugs and obesity and diabetes

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

A meta-analysis of the efficacy of second-generation antipsychotics

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Cataract occurrence with antipsychotic drugs

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

The Mount Sinai conference on the pharmacotherapy of schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Management of weight gain in patients with schizophrenia.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Ziprasidone: profile on safety

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Antipsychotic-induced weight gain: a review of the literature

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Novel antipsychotics: comparison of weight gain liabilities.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Dosing the antipsychotic medication olanzapine

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Physical illness in people with mental disorders.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Myocarditis and cardiomyopathy associated with clozapine use in the United States

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Response to antipsychotic medication: the doctor's and the consumer's view

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

A program for treating olanzapine-related weight gain

30 May 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

[Therapy with antipsychotic drugs as a risk factor for diabetes in schizophrenia: a case-control study].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Comparative study of mortality rates and cardiac dysrhythmias in post-marketing surveillance studies of sertindole and two other atypical antipsychotic drugs, risperidone and olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Sexual dysfunction in schizophrenics patients, the role of antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Prolactin levels and adverse events in patients treated with risperidone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Elevation of prolactin levels by atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Effects of olanzapine and haloperidol on serum prolactin levels in male schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Schizophrenia practice guidelines: international survey and comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Early changes of plasma lipids during treatment with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.2051-5545.2008.TB00154.X

Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2327229

Sexual disorders in nonacute psychiatric outpatients

28 November 2018

1 reference

12 December 2020

Are schizophrenia or antipsychotic drugs a risk factor for cataracts?

1 reference

12 December 2020

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects

1 reference

12 December 2020

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

10.1002/J.2051-5545.2008.TB00154.X

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

1415417

OpenCitations bibliographic resource ID

1415417

1 reference